BHV-2100 is under clinical development by Biohaven and currently in Phase II for Neuropathic Pain (Neuralgia).

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbar radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

Neuropathic pain is caused by disorders of, or damage to, the nervous system. The affected nerves can induce the sensation of pain in the brain. Neuropathic pain is often associated with the ...

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

Cellular research indicates that neuropilin-1 plays a crucial role in pain signaling, presenting a potential pathway for ...

Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...

A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in ...

The efficacy of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy has been established in several controlled clinical trials. [17,18,19] These trials ...

A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

The medication is meant to be a non-addictive alternative to opioids, and has shown in multiple clinical trials the ability to alleviate acute pain as well as a form of chronic nerve pain. Vertex ...

Also Read: MIRA Pharmaceuticals’ Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain The ... successful clinical outcomes. The Phase 1 trial, set to ...

This milestone positions the company for a smoother regulatory pathway, potentially increasing the likelihood of successful clinical outcomes ... of Ketamir-2 in healthy subjects. The trial will ...